Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Review

Risk factors in the development of stem cell therapy

Authors: Carla A Herberts, Marcel SG Kwa, Harm PH Hermsen

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Stem cell therapy holds the promise to treat degenerative diseases, cancer and repair of damaged tissues for which there are currently no or limited therapeutic options. The potential of stem cell therapies has long been recognised and the creation of induced pluripotent stem cells (iPSC) has boosted the stem cell field leading to increasing development and scientific knowledge. Despite the clinical potential of stem cell based medicinal products there are also potential and unanticipated risks. These risks deserve a thorough discussion within the perspective of current scientific knowledge and experience. Evaluation of potential risks should be a prerequisite step before clinical use of stem cell based medicinal products.
The risk profile of stem cell based medicinal products depends on many risk factors, which include the type of stem cells, their differentiation status and proliferation capacity, the route of administration, the intended location, in vitro culture and/or other manipulation steps, irreversibility of treatment, need/possibility for concurrent tissue regeneration in case of irreversible tissue loss, and long-term survival of engrafted cells. Together these factors determine the risk profile associated with a stem cell based medicinal product. The identified risks (i.e. risks identified in clinical experience) or potential/theoretical risks (i.e. risks observed in animal studies) include tumour formation, unwanted immune responses and the transmission of adventitious agents.
Currently, there is no clinical experience with pluripotent stem cells (i.e. embryonal stem cells and iPSC). Based on their characteristics of unlimited self-renewal and high proliferation rate the risks associated with a product containing these cells (e.g. risk on tumour formation) are considered high, if not perceived to be unacceptable. In contrast, the vast majority of small-sized clinical trials conducted with mesenchymal stem/stromal cells (MSC) in regenerative medicine applications has not reported major health concerns, suggesting that MSC therapies could be relatively safe. However, in some clinical trials serious adverse events have been reported, which emphasizes the need for additional knowledge, particularly with regard to biological mechanisms and long term safety.
Literature
1.
Evans MJ, Kaufman MH: Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981, 292: 154-156. 10.1038/292154a0.PubMed
2.
Martin GR: Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proceedings of the National Academy of Sciences of the United States of America. 1981, 78: 7634-7638. 10.1073/pnas.78.12.7634.PubMedCentralPubMed
3.
Thomson JA: Embryonic stem cell lines derived from human blastocysts. Science. 1998, 282: 1145-1147. 10.1126/science.282.5391.1145.PubMed
4.
Solter D: From teratocarcinomas to embryonic stem cells and beyond: A history of embryonic stem cell research. Nature Reviews Genetics. 2006, 7: 319-327. 10.1038/nrg1827.PubMed
5.
Lengner CJ: IPS cell technology in regenerative medicine. Book IPS cell technology in regenerative medicine. 2010, 1192: 38-44. City; 38-44
6.
Bradley A, Evans M, Kaufman MH, Robertson E: Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature. 1984, 309: 255-256. 10.1038/309255a0.PubMed
7.
Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A: Embryonic stem cell lines from human blastocysts: Somatic differentiation in vitro. Nature Biotechnology. 2000, 18: 399-404. 10.1038/74447.PubMed
8.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R: Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007, 318: 1917-1920. 10.1126/science.1151526.PubMed
9.
Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced pluripotent stem cells. Nature. 2007, 448: 313-317. 10.1038/nature05934.PubMed
10.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell. 2007, 131: 861-872. 10.1016/j.cell.2007.11.019.PubMed
11.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell. 2006, 131: 861-872. 10.1016/j.cell.2007.11.019.
12.
Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, Vassena R, Bilic J, Pekarik V, Tiscornia G: Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature Biotechnology. 2008, 26: 1276-1284. 10.1038/nbt.1503.PubMed
13.
Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008, 321: 1218-1221. 10.1126/science.1158799.PubMed
14.
Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R: A Drug-Inducible System for Direct Reprogramming of Human Somatic Cells to Pluripotency. Cell Stem Cell. 2008, 3: 346-353. 10.1016/j.stem.2008.08.014.PubMedCentralPubMed
15.
Takahashi K, Yamanaka S: Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. Cell. 2006, 126: 663-676. 10.1016/j.cell.2006.07.024.PubMed
16.
17.
Saric T, Hescheler J: Stem cells and nuclear reprogramming. Minimally Invasive Therapy and Allied Technologies. 2008, 17: 64-78. 10.1080/13645700801969303.PubMed
18.
Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS: MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells. Cell. 2009, 137: 647-658. 10.1016/j.cell.2009.02.038.PubMed
19.
Geoghegan E, Byrnes L: Mouse induced pluripotent stem cells. International Journal of Developmental Biology. 2008, 52: 1015-1022. 10.1387/ijdb.082640eg.PubMed
20.
Pessina A, Gribaldo L: The key role of adult stem cells: Therapeutic perspectives. Current Medical Research and Opinion. 2006, 22: 2287-2300. 10.1185/030079906X148517.PubMed
21.
Koch P, Kokaia Z, Lindvall O, Brustle O: Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. The Lancet Neurology. 2009, 8: 819-829. 10.1016/S1474-4422(09)70202-9.PubMed
22.
Taupin P, Gage FH: Adult neurogenesis and neural stem cells of the central nervous system in mammals. Journal of Neuroscience Research. 2002, 69: 745-749. 10.1002/jnr.10378.PubMed
23.
Pappa KI, Anagnou NP: Novel sources of fetal stem cells: Where do they fit on the developmental continuum?. Regenerative Medicine. 2009, 4: 423-433. 10.2217/rme.09.12.PubMed
24.
De Coppi P, Bartsch , Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ: Isolation of amniotic stem cell lines with potential for therapy. Nature Biotechnology. 2007, 25: 100-106. 10.1038/nbt1274.PubMed
25.
Prusa AR, Marton E, Rosner M, Bernaschek G, HengstschlaÝĝer M: Oct-4-expressing cells in human amniotic fluid: A new source for stem cell research?. Human Reproduction. 2003, 18: 1489-1493. 10.1093/humrep/deg279.PubMed
26.
Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp D, Tukun A, Uckan D, Can A: Biology of stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem Cells. 2007, 25: 319-331. 10.1634/stemcells.2006-0286.PubMed
27.
Rhodes KE, Gekas C, Wang Y, Lux CT, Francis CS, Chan DN, Conway S, Orkin SH, Yoder MC, Mikkola HKA: The Emergence of Hematopoietic Stem Cells Is - Initiated in the Placental Vasculature in the Absence of Circulation. Cell Stem Cell. 2008, 2: 252-263. 10.1016/j.stem.2008.01.001.PubMedCentralPubMed
28.
Prockop DJ, Olson SD: Clinical trials with adult stem/progenitor cells for tissue repair: Let's not overlook some essential precautions. Blood. 2007, 109: 3147-3151. 10.1182/blood-2006-03-013433.PubMedCentralPubMed
29.
Horwitz EM, Prockop DJ, Gordon PL, Koo WWK, Fitzpatrick LA, Neel MD, McCarville ME, Orchard PJ, Pyeritz RE, Brenner MK: Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001, 97: 1227-1231. 10.1182/blood.V97.5.1227.PubMed
30.
Koc ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplantation. 2002, 30: 215-222. 10.1038/sj.bmt.1703650.PubMed
31.
Lasala GP, Minguell JJ: Bone Marrow-derived Stem/Progenitor Cells: Their Use in Clinical Studies for the Treatment of Myocardial Infarction. Heart Lung and Circulation. 2009, 18: 171-180. 10.1016/j.hlc.2008.09.007.
32.
Bieback K, Kluter H: Mesenchymal stromal cells from umbilical cord blood. Current Stem Cell Research and Therapy. 2007, 2: 310-323. 10.2174/157488807782793763.PubMed
33.
Giordano A, Galderisi U, Marino IR: From the laboratory bench to the patient's bedside: An update on clinical trials with Mesenchymal Stem Cells. Journal of Cellular Physiology. 2007, 211: 27-35. 10.1002/jcp.20959.PubMed
34.
Aranguren XL, Verfaillie CM, Luttun A: Emerging hurdles in stem cell therapy for peripheral vascular disease. Journal of Molecular Medicine. 2009, 87: 3-16. 10.1007/s00109-008-0394-3.PubMed
35.
36.
37.
38.
39.
Li HC, Soticov C, Rogers AB, Houghton JM: Stem cells and cancer: Evidence for bone marrow stem cells in epithelial cancers. World Journal of Gastroenterology. 2006, 12: 363-371.PubMedCentralPubMed
40.
Werbowetski-Ogilvie TE, Bosse M, Stewart M, Schnerch A, Ramos-Mejia V, Rouleau A, Wynder T, Smith MJ, Dingwall S, Carter T: Characterization of human embryonic stem cells with features of neoplastic progression. Nature Biotechnology. 2009, 27: 91-97. 10.1038/nbt.1516.PubMed
41.
Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L: Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Medicine. 2009, 6: 0221-0231. 10.1371/journal.pmed.1000029.
42.
Shih CC, Forman SJ, Chu P, Slovak M: Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells and Development. 2007, 16: 893-902. 10.1089/scd.2007.0070.PubMed
43.
Knoepfler PS: Deconstructing stem cell tumorigenicity: A roadmap to safe regenerative medicine. Stem Cells. 2009, 27: 1050-1056. 10.1002/stem.37.PubMedCentralPubMed
44.
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science. 1977, 197: 461-463. 10.1126/science.560061.PubMed
45.
Bruce WR, Van Der Gaag H: A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963, 199: 79-80. 10.1038/199079a0.PubMed
46.
Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC: Gastric cancer originating from bone marrow-derived cells. Science. 2004, 306: 1568-1571. 10.1126/science.1099513.PubMed
47.
Stark A, Aparisi T, Ericsson JLE: Human osteogenic sarcoma: Fine structure of the osteoblastic type. Ultrastructural Pathology. 1983, 4: 311-329. 10.3109/01913128309140584.PubMed
48.
Barozzi P, Luppi M, Faccheti F, Mecucci C, Alu M, Sarid R, Rasini V, Ravazzini L, Rossi E, Festa S: Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nature Medicine. 2003, 9: 554-561. 10.1038/nm862.PubMed
49.
Aractingi S, Kanitakis J, Euvrard S, Le Danff C, Peguillet I, Khosrotehrani K, Lantz O, Carosella ED: Skin carcinoma arising from donor cells in a kidney transplant recipient. Cancer Research. 2005, 65: 1755-1760. 10.1158/0008-5472.CAN-04-2783.PubMed
50.
Janin A, Murata H, Leboeuf C, Cayuela JM, Gluckman E, Legres L, Desveaux A, Varna M, Ratajczak P, Soulier J: Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood. 2009, 113: 1834-1840. 10.1182/blood-2008-07-171702.PubMed
51.
Ades L, Guardiola P, Socie G: Second malignancies after allogeneic hematopoietic stem cell transplantation: New insight and current problems. Blood Reviews. 2002, 16: 135-146. 10.1054/blre.2002.0010.PubMed
52.
Prokhorova TA, Harkness LM, Frandsen U, Ditzel N, Schroder HD, Burns JS, Kassem M: Teratoma formation by human embryonic stem cells is site dependent and enhanced by the presence of Matrigel. Stem Cells and Development. 2009, 18: 47-54. 10.1089/scd.2007.0266.PubMed
53.
Erdo F, Buhrle C, Blunk J, Hoehn M, Xia Y, Fleischmann B, Focking M, Kustermann E, Kolossov E, Hescheler J: Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. Journal of Cerebral Blood Flow and Metabolism. 2003, 23: 780-785.PubMed
54.
Narva E, Autio R, Rahkonen N, Kong L, Harrison N, Kitsberg D, Borghese L, Itskovitz-Eldor J, Rasool O, Dvorak P: High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity. Nature Biotechnology. 2010, 28: 371-377. 10.1038/nbt.1615.PubMed
55.
Rodriguez R, Rubio R, Masip M, Catalina P, Nieto A, De La Cueva T, Arriero M, Martin NS, De La Cueva E, Balomenos D: Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia. 2009, 11: 397-407.PubMedCentralPubMed
56.
Li H, Fan X, Kovi RC, Jo Y, Moquin B, Konz R, Stoicov C, Kurt-Jones E, Grossman SR, Lyle S: Spontaneous expression of embryonic factors and p53 point mutations in aged mesenchymal stem cells: A model of age-related tumorigenesis in mice. Cancer Research. 2007, 67: 10889-10898. 10.1158/0008-5472.CAN-07-2665.PubMed
57.
Miura Y, Gao Z, Miura M, Seo BM, Sonoyama W, Chen W, Gronthos S, Zhang L, Shi S: Mesenchymal stem cell-organized bone marrow elements: An alternative hematopoietic progenitor resource. Stem Cells. 2006, 24: 2428-2436. 10.1634/stemcells.2006-0089..PubMed
58.
Siebzehnrubl FA, Jeske I, Muller D, Buslei R, Coras R, Hahnen E, Huttner HB, Corbeil D, Kaesbauer J, Appl T: Spontaneous in vitro transformation of adult neural precursors into stem-like cancer cells. Brain Pathology. 2009, 19: 399-408. 10.1111/j.1750-3639.2008.00189.x.PubMed
59.
Kassem M, Burns JS, Castro JG, Munoz DR: Adult stem cells and cancer (multiple letters). Cancer Research. 2005, 65: 9601-10.1158/0008-5472.CAN-05-1541.PubMed
60.
Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montagna D, Maccario R, Villa R, Daidone MG: Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Research. 2007, 67: 9142-9149. 10.1158/0008-5472.CAN-06-4690.PubMed
61.
Tarte K, Gaillard J, Lataillade JJ, Fouillard L, Becker M, Mossafa H, Tchirkov A, Rouard H, Henry C, Splingard M: Clinical-grade production of human mesenchymal stromal cells: Occurrence of aneuploidy without transformation. Blood. 2010, 115: 1549-1553. 10.1182/blood-2009-05-219907.PubMed
62.
Rubio D, Garcia-Castro J, Martin MC, De La Fuente R, Cigudosa JC, Lloyd AC, Bernad A: Spontaneous human adult stem cell transformation. Cancer Research. 2005, 65: 3035-3039.PubMed
63.
Rosland GV, Svendsen A, Torsvik A, Sobala E, McCormack E, Immervoll H, Mysliwietz J, Tonn JC, Goldbrunner R, Lonning PE: Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 2009, 69: 5331-5339. 10.1158/0008-5472.CAN-08-4630.PubMed
64.
Garcia S, Martin MC, De La Fuente R, Cigudosa JC, Garcia-Castro J, Bernad A: Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Experimental Cell Research. 2010, 316: 1648-1650. 10.1016/j.yexcr.2010.02.016.PubMed
65.
Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lonning PE, Primon M, Sobala E, Tonn JC: Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: Putting the research field on track - Letter. Cancer Research. 2010, 70: 6393-6396. 10.1158/0008-5472.CAN-10-1305.PubMed
66.
De La Fuente R, Bernad A, Garcia-Castro J, Martin MC, Cigudosa JC: Retraction: Spontaneous human adult stem cell transformation (Cancer Research (2005) 1). Cancer Research. 2010, 70: 6682-10.1158/0008-5472.CAN-10-2451.PubMed
67.
Lucas S: Chromosomal instability and mesenchymal stem cells. Human Gene Therapy. 2009, 20: 657-664. 10.1089/hum.2009.1601.
68.
Sensebe L, Tarte K, Lataillade JJ, Fouillard L, Rouard H, Tirchkov A, Vernant JP, Gorin NC: Clinical-grade mesenchymal stem/stromal cells: Aneuploidy is not transformation. Human Gene Therapy. 2009, 20: 657-664. 10.1089/hum.2009.1601.
69.
Lepperdinger G, Brunauer R, Jamnig A, Laschober G, Kassem M: Controversial issue: Is it safe to employ mesenchymal stem cells in cell-based therapies?. Experimental Gerontology. 2008, 43: 1018-1023. 10.1016/j.exger.2008.07.004.PubMed
70.
Bushman FD: Retroviral integration and human gene therapy. Journal of Clinical Investigation. 2007, 117: 2083-2086. 10.1172/JCI32949.PubMedCentralPubMed
71.
Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E: LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science. 2003, 302: 415-419. 10.1126/science.1088547.PubMed
72.
Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K: Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature. 2009, 458: 771-775. 10.1038/nature07864.PubMedCentralPubMed
73.
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M: Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors. Cell. 2009, 136: 964-977. 10.1016/j.cell.2009.02.013.PubMedCentralPubMed
74.
Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hamalainen R, Cowling R, Wang W, Liu P, Gertsenstein M: PiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009, 458: 766-770. 10.1038/nature07863.PubMedCentralPubMed
75.
Esteban MA, Gan Y, Qin D, Pei D: Induced pluripotent stem cell (iPS) technology: Promises and challenges. Chinese Science Bulletin. 2009, 54: 2-8. 10.1007/s11434-009-0014-9.
76.
Yamanaka S: A Fresh Look at iPS Cells. Cell. 2009, 137: 13-17. 10.1016/j.cell.2009.03.034.PubMed
77.
Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent stem cells generated without viral integration. Science. 2008, 322: 945-949. 10.1126/science.1162494.PubMedCentralPubMed
78.
Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S: Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008, 322: 949-953. 10.1126/science.1164270.PubMed
79.
Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton DA: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nature Biotechnology. 2008, 26: 1269-1275. 10.1038/nbt.1502.PubMed
80.
Shi Y, Tae Do J, Desponts C, Hahm HS, Scholer HR, Ding S: A Combined Chemical and Genetic Approach for the Generation of Induced Pluripotent Stem Cells. Cell Stem Cell. 2008, 2: 525-528. 10.1016/j.stem.2008.05.011.PubMed
81.
Uccelli A, Moretta L, Pistoia V: Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008, 8: 726-736. 10.1038/nri2395.PubMed
82.
Lazennec G, Jorgensen C: Concise review: Adult multipotent stromal cells and cancer: Risk or benefit?. Stem Cells. 2008, 26: 1387-1394. 10.1634/stemcells.2007-1006.PubMedCentralPubMed
83.
Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y: The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia. 2008, 22: 593-599. 10.1038/sj.leu.2405090.PubMed
84.
Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003, 102: 3837-3844. 10.1182/blood-2003-04-1193.PubMed
85.
Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007, 449: 557-563. 10.1038/nature06188.PubMed
86.
Nussbaum J, Minami E, Laflamme MA, Virag JAI, Ware CB, Masino A, Muskheli V, Pabon L, Reinecke H, Murry CE: Transplantation of undifferentiated murine embryonic stem cells in the heart: Teratoma formation and immune response. FASEB Journal. 2007, 21: 1345-1357. 10.1096/fj.06-6769com.PubMed
87.
Li L, Baroja ML, Majumdar A, Chadwick K, Rouleau A, Gallacher L, Ferber I, Lebkowski J, Martin T, Madrenas J, Bhatia M: Human embryonic stem cells possess immune-privileged properties. Stem Cells. 2004, 22: 448-456. 10.1634/stemcells.22-4-448.PubMed
88.
Drukker M, Katchman H, Katz G, Friedman SET, Shezen E, Hornstein E, Mandelboim O, Reisner Y, Benvenisty N: Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells. 2006, 24: 221-229. 10.1634/stemcells.2005-0188.PubMed
89.
Mohib K, Allan D, Wang L: Human Embryonic Stem Cell-extracts Inhibit the Differentiation and Function of Monocyte-derived Dendritic Cells. Stem Cell Reviews and Reports. 2010, 6: 611-621. 10.1007/s12015-010-9185-7.PubMed
90.
Nasef A, Ashammakhi N, Fouillard L: Immunomodulatory effect of mesenchymal stromal cells: Possible mechanisms. Regenerative Medicine. 2008, 3: 531-546. 10.2217/17460751.3.4.531.PubMed
91.
Chamberlain G, Fox J, Ashton B, Middleton J: Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007, 25: 2739-2749. 10.1634/stemcells.2007-0197.PubMed
92.
Nakatsuji N, Nakajima F, Tokunaga K: HLA-haplotype banking and iPS cells. Nature Biotechnology. 2008, 26: 739-740. 10.1038/nbt0708-739.PubMed
93.
Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. The Lancet. 2008, 371: 1579-1586. 10.1016/S0140-6736(08)60690-X.
94.
Kainer MA, Linden JV, Whaley DN, Holmes HT, Jarvis WR, Jernigan DB, Archibald LK: Clostridium infections associated with musculoskeletal-tissue allografts. NEnglJMed. 2004, 350: 2564-2571. 10.1056/NEJMoa023222.
95.
Tugwell BD, Patel PR, Williams IT, Hedberg K, Chai F, Nainan OV, Thomas AR, Woll JE, Bell BP, Cieslak PR: Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. AnnInternMed. 2005, 143: 648-654.
96.
Sundin M, Orvell C, Rasmusson I, Sundberg B, Ringden O, Le Blanc K: Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplantation. 2006, 37: 1051-1059. 10.1038/sj.bmt.1705368.PubMed
97.
Martin MJ, Muotri A, Gage F, Varki A: Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nature Medicine. 2005, 11: 228-232. 10.1038/nm1181.PubMed
98.
Menasche P: Stem cell therapy for heart failure: Are arrhythmias a real safety concern?. Circulation. 2009, 119: 2735-2740. 10.1161/CIRCULATIONAHA.108.812693.PubMed
99.
Grigg A, Gibson R, Bardy P, Szer J: Acute portal vein thrombosis after autologous stem cell transplantation. Bone Marrow Transplantation. 1996, 18: 949-953.PubMed
100.
Kikuchi K, Rudolph R, Murakami C, Kowdley K, McDonald GB: Portal vein thrombosis after hematopoietic cell transplantation: Frequency, treatment and outcome. Bone Marrow Transplantation. 2002, 29: 329-333. 10.1038/sj.bmt.1703368.PubMed
101.
Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, Fries JWU, Tiemann K, Bohlen H, Hescheler J: Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007, 110: 1362-1369. 10.1182/blood-2006-12-063412.PubMed
102.
Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D: Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. JNeurosci. 2007, 27: 8011-8022. 10.1523/JNEUROSCI.2079-07.2007.
103.
Vogel G: To scientists' dismay, mixed-up cell lines strike again. Science. 2010, 329: 1004-10.1126/science.329.5995.1004.PubMed
104.
Ruckdeschel Smith R, Barile L, Messina E, Marban E: Stem cells in the heart: What's the buzz all about? Part 2: Arrhythmic risks and clinical studies. Heart Rhythm. 2008, 5: 880-887. 10.1016/j.hrthm.2008.02.011.
105.
Germani A, Di Campli C, Pompilio G, Biglioli P, Capogrossi MC: Regenerative therapy in peripheral artery disease. Cardiovascular Therapeutics. 2009, 27: 289-304. 10.1111/j.1755-5922.2009.00105.x.PubMed
106.
Tendera M, Wojakowski W: Cell therapy - Success does not come easy. European Heart Journal. 2009, 30: 640-641. 10.1093/eurheartj/ehp066.PubMed
107.
108.
109.
Pearson JD: Endothelial progenitor cells - Hype or hope?. Journal of Thrombosis and Haemostasis. 2009, 7: 255-262. 10.1111/j.1538-7836.2008.03214.x.PubMed
Metadata
Title
Risk factors in the development of stem cell therapy
Authors
Carla A Herberts
Marcel SG Kwa
Harm PH Hermsen
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-29

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue

Research

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

Research

Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages

Research

Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2

Review

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting

Review

An immunologic portrait of cancer

Research

Cytotoxic T lymphocyte responses against melanocytes and melanoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits